Larkspur Health Acquisition Corp.
Status: Deal Closed
U=S+(3/4)W
W=S@11.5
IPO Proceeds, $M | $77.67M |
---|---|
IPO Date | Dec 21, 2021 |
Left Lead | A.G.P |
IPO Cash in Trust | 101.0% |
SPAC Tenor | 12 + (2*3) |
IPO Sector |
Healthcare
Biotechnology in the US |
IPO Geography | US/Canada |
Target Company | ZyVersa Therapeutics |
Deal Announced | Jul 21, 2022 |
Deal Size, $M | $108.92M |
Deal Sector | Healthcare |
Deal Geography | US/Canada |
SEC Filings | www.sec.gov |
Approval Vote | Dec 8, 2022 |
Amendment Vote | TBD |
Closing Date | Dec 12, 2022 |
Formerly LSPR
ZVSA
ZVSAW
Price | $1.10 $0.00 |
---|---|
Last closing price | $1.12 |
H/L, today | $1.07 / $1.13 |
H/L, 52-week | $0.07 / $24.29 |
Volume, today | 7,900 |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Larkspur Health Acquisition Corp.:
- Structure and cap table
- 5 directors & officers
- 28 filings and events
- 3 underwriters
- 2 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Daniel J. O'Connor | 57 | Chairman, CFO and Director |
David S. Briones | 45 | CFO and Treasurer and Director |
Raj Mehra, Ph.D., J.D. | 60 | Director |
Gregory Skalicky | 49 | Director |
Christopher Twitty, Ph.D. | 49 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
A.G.P | BR | 5,066,668 | units |
Brookline Capital Markets | 766,666 | ||
The Benchmark Company | 1,666,666 | ||
7,500,000 | units | ||
Up-Front UW fee | 2.00 | % | |
BCMA | 4.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.